Engineered immune cells take on tough lung cancer

NCT ID NCT07564401

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new treatment called DJI136, which uses a patient's own immune cells engineered to target a protein (DLL3) found on small cell lung cancer cells. The trial enrolls 80 adults with extensive-stage small cell lung cancer whose disease has progressed after standard treatments. The goal is to find the right dose and check if the therapy is safe and shows signs of shrinking tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DJI136 (a DLL3-targeted CAR-T cell therapy)
What this could lead to: If successful, this could offer a new treatment option for people with advanced small cell lung cancer who have run out of standard therapies.
What could go wrong: This is an early-phase trial (Phase I/II) with only 80 participants, so safety and effectiveness are not yet proven. CAR-T therapies can cause severe side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)

Contacts and locations

Locations

Fred Hutchinson Cancer Center
RECRUITING

Seattle, Washington, 98109, United States
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Novartis Investigative Site
RECRUITING

Singapore, 168583, Singapore
University of Kentucky
RECRUITING

Lexington, Kentucky, 40536, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.